Epidemiological findings of vascular risk factors in Alzheimer's disease: Implications for therapeutic and preventive intervention

Expert Review of Neurotherapeutics

Volumn 11, Issue 11, 2011, Pages 1593-1607

  Qiu, Chengxuan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Alzheimer's disease; cardiovascular risk factors; cerebral microvascular disease; epidemiology; neurodegeneration; prevention; therapeutics

Indexed keywords

ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CELECOXIB; ESTROGEN; GESTAGEN; GINKGO BILOBA EXTRACT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; PLACEBO; RAMIPRIL; SIMVASTATIN; TELMISARTAN;

ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; BRAIN ATROPHY; CARDIOVASCULAR RISK; CEREBRAL SMALL VESSEL DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DEMENTIA; DIABETES MELLITUS; DIET; DYSLIPIDEMIA; ESTROGEN THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INFLAMMATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; REVIEW; STROKE; SYSTEMATIC REVIEW (TOPIC); TRANSIENT ISCHEMIC ATTACK;

CARDIOVASCULAR DISEASES; HUMANS; RISK FACTORS; VASCULAR DISEASES;

EID: 80054937597     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.146     Document Type: Review

References (176)

1. Fratiglioni L, Launer LJ, Andersen K et al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 54(11 Suppl. 5), S10-S15 (2000)
2. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat. Rev. Neurol. 7, 137-152 (2011)
3. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 21, 153-160 (2000)
4. Geldmacher DS. Alzheimer disease prevention: focus on cardiovascular risk, not amyloid? Cleve. Clin. J Med. 77, 689-704 (2010)
5. Stanziano DC, Whitehurst M, Graham P, Roos BA. A review of selected longitudinal studies on aging: past findings and future directions. J Am. Geriatr. Soc. 58(Suppl. 2), S292-S297 (2010)
6. Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors for Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis. 20, 689-697 (2010)
7. Barnes DE, Haight TJ, Mehta KM, Carlson MC, Kuller LH, Tager IB. Secondhand smoke, vascular disease, and dementia incidence: findings from the Cardiovascular Health Cognition Study. Am. J Epidemiol. 171, 292-302 (2010)
8. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am. J Epidemiol. 166, 367-378 (2007)
9. Peters R, Poulter R, Warner J, Beckett N, Burch L, Bulpitt C. Smoking, dementia and cognitive decline in the elderly: a systematic review. BMC Geriatr. 8, 36 (2008)
10. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis. 19, 465-480 (2010)
11. Rusanen M, Rovio S, Ngandu T et al. Midlife smoking, apolipoprotein E and risk of dementia and Alzheimer's disease: a population-based Cardiovascular Risk Factors, Aging and Dementia study. Dement. Geriatr. Cogn. Disord. 30, 277-284 (2010)
12. Rusanen M, Kivipelto M, Quesenberry CP Jr, Zhou J, Whitmer RA. Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch. Intern. Med. 171, 333-339 (2011)
13. Alonso A, Jacobs DR Jr, Menotti A et al. Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J Neurol. Sci. 280(1-2), 79-83 (2009)
14. Hernán MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology 19, 448-450 (2008)
15. Tyas SL, White LR, Petrovitch H et al. Mid-life smoking and late-life dementia: the Honolulu-Asia Aging Study. Neurobiol. Aging 24, 589-596 (2003)
16. Anttila T, Helkala EL, Viitanen M et al. Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. BMJ 329, 539 (2004)
17. Peters R, Peters J, Warner J, Beckett N, Bulpitt C. Alcohol, dementia and cognitive decline in the elderly: a systematic review. Age Ageing 37, 505-512 (2008)
18. Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. Am. J Geriatr. Psychiatry 17, 542-555 (2009)
19. Larson EB, Wang L, Bowen JD et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern. Med. 144, 73-81 (2006)
20. Scarmeas N, Luchsinger JA, Brickman AM et al. Physical activity and Alzheimer disease course. Am. J Geriatr. Psychiatry 19, 471-481 (2011)
21. Scarmeas N, Luchsinger JA, Schupf N et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 302, 627-637 (2009)
22. Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol. Med. 39, 3-11 (2009)
23. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol. 4, 487-499 (2005)
24. Alonso A, Mosley TH, Gottesman RF, Catellier D, Sharrett AR, Coresh J. Risk of dementia hospitalisation associated with cardiovascular risk factors in midlife and older age: the Atherosclerosis Risk in Communities (ARIC) study. J Neurol. Neurosurg. Psychiatry 80, 1194-1201 (2009)
25. Launer LJ, Hughes T, Yu B et al. Lowering midlife levels of systolic blood pressure as a public health strategy to reduce late-life dementia: perspective from the Honolulu Heart Program/Honolulu Asia Aging Study. Hypertension 55, 1352-1359 (2010)
26. Bermejo-Pareja F, Benito-León J, Louis ED et al. Risk of incident dementia in drug-untreated arterial hypertension: a population-based study. J Alzheimers Dis. 22, 949-958 (2010)
27. Qiu C, Winblad B, Fratiglioni L. Low diastolic pressure and risk of dementia in very old people: a longitudinal study. Dement. Geriatr. Cogn. Disord. 28, 213-219 (2009)
28. Li G, Rhew IC, Shofer JB et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am. Geriatr. Soc. 55, 1161-1167 (2007)
29. Johnson KC, Margolis KL, Espeland MA et al. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women's Health Initiative Memory Study. J Am. Geriatr. Soc. 56, 1449-1458 (2008)
30. Euser SM, van Bemmel T, Schram MT et al. The effect of age on the association between blood pressure and cognitive function later in life. J Am. Geriatr. Soc. 57, 1232-1237 (2009)
31. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and the risk for dementia: a double edged sword. Ageing Res. Rev. 8, 61-70 (2009)
32. Novak V, Hajjar I. The relationship between blood pressure and cognitive function. Nat. Rev. Cardiol. 7, 686-698 (2010)
33. Rosengren A, Skoog I, Gustafson D, Wilhelmsen L. Body mass index, other cardiovascular risk factors, and hospitalization for dementia. Arch. Intern. Med. 165, 321-326 (2005)
34. Beydoun MA, Lhotsky A, Wang Y et al. Association of adiposity status and changes in early to mid-adulthood with incidence of Alzheimer's disease. Am. J Epidemiol. 168, 1179-1189 (2008)
35. Hassing LB, Dahl AK, Thorvaldsson V et al. Overweight in midlife and risk of dementia: a 40-year follow-up study. Int. J Obes. (Lond.) 33, 893-898 (2009)
36. Fitzpatrick AL, Kuller LH, Lopez OL et al. Midlife and late-life obesity and the risk of dementia: the Cardiovascular Health Study. Arch. Neurol. 66, 336-342 (2009)
37. Gustafson DR, Bäckman K, Waern M et al. Adiposity indicators and dementia over 32 years in Sweden. Neurology 73, 1559-1566 (2009)
38. Atti AR, Palmer K, Volpato S, Winblad B, De Ronchi D, Fratiglioni L. Late-life body mass index and dementia incidence: nine-year follow-up data from the Kungsholmen Project. J Am. Geriatr. Soc. 56, 111-116 (2008)
39. Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes. Rev. 9, 204-218 (2008)
40. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol. Psychiatry 67, 505-512 (2010)
41. Gustafson D. A life course of adiposity and dementia. Eur J. Pharmacol. 585, 163-175 (2008)
42. Solomon A, Kivipelto M. Cholesterol-modifying strategies for Alzheimer's disease. Expert Rev. Neurother. 9, 695-709 (2009)
43. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am. J Geriatr. Psychiatry 16, 343-354 (2008)
44. Stewart R, White LR, Xue QL, Launer LJ. Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. Arch. Neurol. 64, 103-107 (2007)
45. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch. Neurol. 67, 1491-1497 (2010)
46. Scarmeas N, Stern Y, Mayeux R, Luchsinger JA. Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 63, 1709-1717 (2006)
47. Féart C, Samieri C, Rondeau V et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA 302, 638-648 (2009)
48. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch. Neurol. 67, 699-706 (2010)
49. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: a complex association. Nat. Clin. Pract. Neurol. 5, 140-152 (2009)
50. Devore EE, Grodstein F, van Rooij FJ et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am. J Clin. Nutr. 90, 170-176 (2009)
51. Kröger E, Verreault R, Carmichael PH et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am. J Clin. Nutr. 90, 184-192 (2009)
52. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease. Lancet Neurol. 3, 579-587 (2004)
53. Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Relation of higher folate intake to lower risk of Alzheimer disease in the elderly. Arch. Neurol. 64(1), 86-92 (2007)
54. Luchsinger JA, Tang MX, Miller J, Green R, Mayeux R. Higher folate intake is related to lower risk of Alzheimer's disease in the elderly. J Nutr. Health Aging 12, 648-650 (2008)
55. Hooshmand B, Solomon A, Kreholt I et al. Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology 75, 1408-1414 (2010)
56. Malouf R, Evans JG. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database Syst. Rev. CD004514 (2008)
57. van Dam F, van Gool WA. Hyperhomocysteinemia and Alzheimer's disease: a systematic review. Arch. Gerontol. Geriatr. 48, 425-430 (2009)
58. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst. Rev. 352(23), 2379-2388 (2008)
59. Kopf D, Frölich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis. 16, 677-685 (2009)
60. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 4, e4144 (2009)
61. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid-and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 58, 71-77 (2009)
62. Xu W, Qiu C, Winblad B, Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56, 211-216 (2007)
63. Xu W, Caracciolo B, Wang HX et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 59, 2928-2935 (2010)
64. Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with Type 2 diabetes mellitus. JAMA 301, 1565-1572 (2009)
65. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 52, 168-174 (2002)
66. van Exel E, Eikelenboom P, Comijs H et al. Vascular factors and markers of inflammation in offspring with a parental history of late-onset Alzheimer disease. Arch. Gen. Psychiatry 66, 1263-1270 (2009)
67. Engelhart MJ, Geerlings MI, Meijer J et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam study. Arch. Neurol. 61, 668-672 (2004)
68. Tan ZS, Beiser AS, Vasan RS et al. Inflammatory markers and the risk of Alzheimer disease: the Framingham study. Neurology 68, 1902-1908 (2007)
69. Sundelöf J, Kilander L, Helmersson J et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis. 18(1), 79-87 (2009)
70. Muller M, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. Metabolic syndrome and dementia risk in a multiethnic elderly cohort. Dement. Geriatr. Cogn. Disord. 24, 185-192 (2007)
71. Raffaitin C, Gin H, Empana JP et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32, 169-174 (2009)
72. Forti P, Pisacane N, Rietti E et al. Metabolic syndrome and risk of dementia in older adults. J Am. Geriatr. Soc. 58, 487-492 (2010)
73. Vanhanen M, Koivisto K, Moilanen L et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67, 843-847 (2006)
74. Solfrizzi V, Scafato E, Capurso C et al. Metabolic syndrome and the risk of vascular dementia: the Italian Longitudinal Study on Ageing. J Neurol. Neurosurg. Psychiatry 81, 433-440 (2010)
75. Luchsinger JA, Gustafson DR. Adiposity, Type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis. 16, 693-704 (2009)
76. van Oijen M, de Jong FJ, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM. Atherosclerosis and risk for dementia. Ann Neurol. 61, 403-410 (2007)
77. Laurin D, Masaki KH, White LR, Launer LJ. Ankle-to-brachial index and dementia: the Honolulu-Asia Aging Study. Circulation 116, 2269-2274 (2007)
78. Elias MF, Robbins MA, Budge MM, Abhayaratna WP, Dore GA, Elias PK. Arterial pulse wave velocity and cognition with advancing age. Hypertension 53, 668-673 (2009)
79. Wendell CR, Zonderman AB, Metter EJ, Najjar SS, Waldstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 40, 3180-3185 (2009)
80. Sander K, Bickel H, Förstl H et al. Carotid-intima media thickness is independently associated with cognitive decline: the INVADE study. Int. J Geriatr. Psychiatry 25, 389-394 (2010)
81. Vidal JS, Sigurdsson S, Jonsdottir MK et al. Coronary artery calcium, brain function and structure: the AGES-Reykjavik Study. Stroke 41, 891-897 (2010)
82. Ikram MA, van Oijen M, de Jong FJ et al. Unrecognized myocardial infarction in relation to risk of dementia and cerebral small vessel disease. Stroke 39, 1421-1426 (2008)
83. Bursi F, Rocca WA, Killian JM et al. Heart disease and dementia: a population-based study. Am. J Epidemiol. 163, 135-141 (2006)
84. Qiu C, Winblad B, Marengoni A, Klarin I, Fastbom J, Fratiglioni L. Heart failure and risk of dementia and Alzheimer disease: a population-based cohort study. Arch. Intern. Med. 166, 1003-1008 (2006)
85. Newman AB, Fitzpatrick AL, Lopez O et al. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am. Geriatr. Soc. 53, 1101-1107 (2005)
86. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 8, 1006-1018 (2009)
87. Savva GM, Stephan BCM. Epidemiological studies of the effect of stroke on incident dementia: a systematic review. Stroke 41, E41-E46 (2010)
88. Purandare N, Burns A, Daly KJ et al. Cerebral emboli as a potential cause of Alzheimer's disease and vascular dementia: case-control study. BMJ 332, 1119-1122 (2006)
89. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64, 277-281 (2005)
90. Luchsinger JA, Reitz C, Honig LS, Tang MX, Shea S, Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 65, 545-551 (2005)
91. Qiu C, Xu W, Winblad B, Fratiglioni L. Vascular risk profiles for dementia and Alzheimer's disease in very old people: a population-based longitudinal study. J Alzheimers Dis. 20, 293-300 (2010)
92. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 5, 735-741 (2006)
93. Barnes DE, Covinsky K, Whitmer RA, Kuller LH, Lopez OL, Yaffe K. Predicting risk of dementia in older adults: the late-life dementia risk index. Neurology 73, 173-179 (2009)
94. Reitz C, Tang MX, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. Arch. Neurol. 67, 835-841 (2010)
95. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 73, 674-680 (2009)
96. Li J, Wang YJ, Zhang M et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 76, 1485-1491 (2011)
97. Greenberg SM, Vernooij MW, Cordonnier C et al. Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol. 8, 165-174 (2009)
98. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 9, 689-701 (2010)
99. Vernooij MW, van der Lugt A, Ikram MA et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurology 70, 1208-1214 (2008)
100. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet Neurol. 6, 611-619 (2007)
101. Qiu C, Cotch MF, Sigurdsson S et al. Retinal and cerebral microvascular signs and diabetes: the Age, Gene/Environment Susceptibility -Reykjavik Study. Diabetes 57, 1645-1650 (2008)
102. Hajjar I, Quach L, Yang F et al. Hypertension, white matter hyperintensities, and concurrent impairments in mobility, cognition, and mood: the Cardiovascular Health Study. Circulation 123, 858-865 (2011)
103. Troncoso JC, Zonderman AB, Resnick SM, Crain B, Pletnikova O, O'Brien RJ. Effect of infarcts on dementia in the Baltimore Longitudinal Study of Aging. Ann Neurol. 64, 168-176 (2008)
104. Honig LS, Tang MX, Albert S et al. Stroke and the risk of Alzheimer disease. Arch. Neurol. 60, 1707-1712 (2003)
105. Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ 341, c3666 (2010)
106. Debette S, Beiser A, DeCarli C et al. Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. Stroke 41, 600-606 (2010)
107. Silbert LC, Howieson DB, Dodge H, Kaye JA. Cognitive impairment risk: white matter hyperintensity progression matters. Neurology 73, 120-125 (2009)
108. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: the Rotterdam Scan study. Stroke 39, 2712-2719 (2008)
109. Esiri M, Nagy Z, Smith MZ, Barnetson L, Smith AD. Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer's disease. Lancet 354, 919-920 (1999)
110. Ahtiluoto S, Polvikoski T, Peltonen M et al. Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology 75, 1195-1202 (2010)
111. Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer's disease in the BLSA cohort. Ann Neurol. 68, 231-240 (2010)
112. Wharton SB, Brayne C, Savva GM et al. Epidemiological neuropathology: the MRC Cognitive Function and Aging Study experience. J Alzheimers Dis. 25, 359-372 (2011)
113. Roher AE, Esh C, Kokjohn TA et al. Circle of Willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler. Thromb. Vasc. Biol. 23, 2055-2062 (2003)
114. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet 363, 1139-1146 (2004)
115. Honig LS, Kukull W, Mayeux R. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. Neurology 64, 494-500 (2005)
116. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58, 1476-1482 (2002)
117. Barkhof F, Polvikoski TM, van Straaten EC et al. The significance of medial temporal lobe atrophy: a postmortem MRI study in the very old. Neurology 69, 1521-1527 (2007)
118. Jagust WJ, Zheng L, Harvey DJ et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol. 63, 72-80 (2008)
119. Peila R, Rodriguez B, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 51, 1256-1262 (2002)
120. Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension 44, 29-34 (2004)
121. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5, 64-74 (2006)
122. Launer LJ, Petrovitch H, Ross GW, Markesbery W, White LR. AD brain pathology: vascular origins? Results from the HAAS autopsy study. Neurobiol. Aging 29, 1587-1590 (2008)
123. van Elderen SG, de Roos A, de Craen A et al. Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 75, 997-1002 (2010)
124. Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM. Prestroke cognitive performance, incident stroke, and risk of dementia: the Rotterdam Study. Stroke 39, 36-41 (2008)
125. Firbank MJ, Burton EJ, Barber R et al. Medial temporal atrophy rather than white matter hyperintensities predict cognitive decline in stroke survivors. Neurobiol. Aging 28, 1664-1669 (2007)
126. Fournier A, Oprisiu-Fournier R, Serot JM et al. Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Rev. Neurother. 9, 1413-1431 (2009)
127. Shah K, Qureshi SU, Johnson M, Parikh N, Schulz PE, Kunik ME. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J Geriatr. Pharmacother. 7, 250-261 (2009)
128. Duron E, Hanon O. Antihypertensive treatments, cognitive decline, and dementia. J Alzheimers Dis. 20, 903-914 (2010)
129. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 37, 1165-1170 (2006)
130. Haag MD, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. Duration of antihypertensive drug use and risk of dementia: a prospective cohort study. Neurology 72, 1727-1734 (2009)
131. Li NC, Lee A, Whitmer RA et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 340, B5465 (2010)
132. Hoffman LB, Schmeidler J, Lesser GT et al. Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72, 1720-1726 (2009)
133. Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162, 2046-2052 (2002)
134. Tzourio C, Anderson C, Chapman N et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 163, 1069-1075 (2003)
135. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7, 683-689 (2008)
136. Anderson C, Teo K, Gao P et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 10, 43-53 (2011)
137. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev. CD004034 (2009)
138. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 21, 875-886 (2003)
139. Staessen JA, Thijs L, Richart T, Odili AN, Birkenhäger WH. Placebo-controlled trials of blood pressure-lowering therapies for primary prevention of dementia. Hypertension 57, E6-E7 (2011)
140. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327, 128 (2003)
141. Szekely CA, Zandi PP. Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. CNS Neurol. Disord. 9, 132-139 (2010)
142. Arvanitakis Z, Grodstein F, Bienias JL et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70, 2219-2225 (2008)
143. Lyketsos CG, Breitner JC, Green RC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68, 1800-1808 (2007)
144. Martin BK, Szekely C, Brandt J et al. Cognitive function over time in the Alzheimer's disease anti-inflammatory prevention trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65, 896-905 (2008)
145. Sonnen JA, Larson EB, Walker RL et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 75, 1203-1210 (2010)
146. Meinert CL, Breitner JC. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement. 4(1 Suppl. 1), S7-S14 (2008)
147. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 279, 688-695 (1998)
148. Craig MC, Murphy DG. Estrogen therapy and Alzheimer's dementia. Ann NY Acad. Sci. 1205, 245-253 (2010)
149. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2651-2662 (2003)
150. Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study. JAMA 291, 2947-2958 (2004)
151. Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: the critical window theory revisited. Ann Neurol. 69, 163-169 (2011)
152. Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst. Rev. CD003799 (2009)
153. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study. J Am. Geriatr. Soc. 50, 1852-1856 (2002)
154. Li G, Larson EB, Sonnen JA et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69, 878-885 (2007)
155. Arvanitakis Z, Schneider JA, Wilson RS et al. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802 (2008)
156. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst. Rev. CD003160 (2009)
157. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst. Rev. CD007514 (2010)
158. Feldman HH, Doody RS, Kivipelto M et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964 (2010)
159. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300, 2253-2262 (2008)
160. Snitz BE, O'Meara ES, Carlson MC et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA 302, 2663-2670 (2009)
161. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. CD003120 (2009)
162. Weinmann S, Roll S, Schwarzbach C, Vauth C, Willich SN. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 10, 14 (2010)
163. Janssen IM, Sturtz S, Skipka G, Zentner A, Garrido MV, Busse R. Ginkgo biloba in Alzheimer's disease: a systematic review. Wien. Med. Wochenschr. 160, 539-546 (2010)
164. Daviglus ML, Bell CC, Berrettini W et al. National Institutes of Health State-of-the-Science Conference Statement: preventing Alzheimer disease and cognitive decline. Ann Intern. Med.153, 176-181 (2010)
165. Viswanathan A, Rocca WA, Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology 72, 368-374 (2009)
166. Qiu C, Kivipelto M, Fratiglioni L. Preventing Alzheimer disease and cognitive decline. Ann Intern. Med. 154, 211 (2011)
167. Li G, Shofer JB, Rhew IC et al. Age-varying association between statin use and incident Alzheimer's disease. J Am. Geriatr. Soc. 58, 1311-1317 (2010)
168. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N. Engl. J Med. 360, 2302-2309 (2009)
169. Whitlock G, Lewington S, Sherliker P et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373, 1083-1096 (2009)
170. Whalley LJ, Dick FD, McNeill G. A life-course approach to the aetiology of late-onset dementias. Lancet Neurol. 5, 87-96 (2006)
171. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ 341, c3885 (2010)
172. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch. Neurol. 66, 1210-1215 (2009)
173. Fratiglioni L, Qiu C. Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal. Lancet Neurol. 10, 778-779 (2011)
174. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 7, 436-450 (2008)
175. Aisen PS, Andrieu S, Sampaio C et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76, 280-286 (2011)
176. Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study http://clinicaltrials.gov/ct2/results?term=NCT00053599